Covidien, a provider of healthcare products, is set to launch TurboHawk Plaque Excision System for small vessels, in the US and several international markets.
The new system is US Food and Drug Administration 510(k) cleared and is intended to treat calcified and non-calcified lesion morphologies in small vessels, broadening minimally-invasive treatment options for peripheral arterial disease (PAD).
The TurboHawk device design allows for greater cutting efficiency, providing physicians access to a device with more consistent performance, Covidien said.
Covidien Peripheral Vascular president Stacy Enxing Seng said the TurboHawk system for small vessels extends the capabilities demonstrated by TurboHawk Super and Smooth Cutter above the knee to smaller, below the knee vessels, which translates to improved delivery and improved plaque excision of mild to moderately calcified vessels.
Covidien Vascular Therapies president Joe Woody said the TurboHawk Plaque Excision System for small vessels will provide physicians and healthcare professionals with a minimally invasive solution that can improve patient outcomes in the treatment of PAD.